These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. Pagliardini V; Pagliardini S; Corrado L; Lucenti A; Panigati L; Bersano E; Servo S; Cantello R; D'Alfonso S; Mazzini L J Neurol Sci; 2015 Jan; 348(1-2):245-50. PubMed ID: 25563799 [TBL] [Abstract][Full Text] [Related]
28. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. Hartikainen P; Reinikainen KJ; Soininen H; Sirviö J; Soikkeli R; Riekkinen PJ J Neural Transm Park Dis Dement Sect; 1992; 4(1):53-68. PubMed ID: 1347220 [TBL] [Abstract][Full Text] [Related]
29. YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Andrés-Benito P; Domínguez R; Colomina MJ; Llorens F; Povedano M; Ferrer I Aging (Albany NY); 2018 Sep; 10(9):2367-2382. PubMed ID: 30215603 [TBL] [Abstract][Full Text] [Related]
30. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Sjögren M; Davidsson P; Wallin A; Granérus AK; Grundström E; Askmark H; Vanmechelen E; Blennow K Dement Geriatr Cogn Disord; 2002; 13(2):112-8. PubMed ID: 11844893 [TBL] [Abstract][Full Text] [Related]
31. Chitinases as a potential diagnostic and prognostic biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. Xu A; Luo Y; Tang Y; Yang F; Gao X; Qiao G; Zhu X; Zhou J Neurol Sci; 2024 Jun; 45(6):2489-2503. PubMed ID: 38194198 [TBL] [Abstract][Full Text] [Related]
32. Microglial upregulation of progranulin as a marker of motor neuron degeneration. Philips T; De Muynck L; Thu HN; Weynants B; Vanacker P; Dhondt J; Sleegers K; Schelhaas HJ; Verbeek M; Vandenberghe R; Sciot R; Van Broeckhoven C; Lambrechts D; Van Leuven F; Van Den Bosch L; Robberecht W; Van Damme P J Neuropathol Exp Neurol; 2010 Dec; 69(12):1191-200. PubMed ID: 21107132 [TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study. Zucchi E; Bedin R; Fasano A; Fini N; Gessani A; Vinceti M; Mandrioli J Neurodegener Dis; 2018; 18(5-6):255-261. PubMed ID: 30428468 [TBL] [Abstract][Full Text] [Related]
34. CHIT1 at Diagnosis Reflects Long-Term Multiple Sclerosis Disease Activity. Oldoni E; Smets I; Mallants K; Vandebergh M; Van Horebeek L; Poesen K; Dupont P; Dubois B; Goris A Ann Neurol; 2020 Apr; 87(4):633-645. PubMed ID: 31997416 [TBL] [Abstract][Full Text] [Related]
35. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Lill CM; Rengmark A; Pihlstrøm L; Fogh I; Shatunov A; Sleiman PM; Wang LS; Liu T; Lassen CF; Meissner E; Alexopoulos P; Calvo A; Chio A; Dizdar N; Faltraco F; Forsgren L; Kirchheiner J; Kurz A; Larsen JP; Liebsch M; Linder J; Morrison KE; Nissbrandt H; Otto M; Pahnke J; Partch A; Restagno G; Rujescu D; Schnack C; Shaw CE; Shaw PJ; Tumani H; Tysnes OB; Valladares O; Silani V; van den Berg LH; van Rheenen W; Veldink JH; Lindenberger U; Steinhagen-Thiessen E; ; Teipel S; Perneczky R; Hakonarson H; Hampel H; von Arnim CAF; Olsen JH; Van Deerlin VM; Al-Chalabi A; Toft M; Ritz B; Bertram L Alzheimers Dement; 2015 Dec; 11(12):1407-1416. PubMed ID: 25936935 [TBL] [Abstract][Full Text] [Related]
36. Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis. Gong ZY; Lv GP; Gao LN; Lu Y; Guo J; Zang DW Neurodegener Dis; 2018; 18(2-3):165-172. PubMed ID: 29898446 [TBL] [Abstract][Full Text] [Related]
37. Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: morphometric study and review of the literature. Wojtera M; Sobów T; Kłoszewska I; Liberski PP; Brown DR; Sikorska B Folia Neuropathol; 2012; 50(1):74-84. PubMed ID: 22505366 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Chen X; Hu Y; Cao Z; Liu Q; Cheng Y Front Immunol; 2018; 9():2122. PubMed ID: 30283455 [TBL] [Abstract][Full Text] [Related]
39. Serotonin 2B receptor slows disease progression and prevents degeneration of spinal cord mononuclear phagocytes in amyotrophic lateral sclerosis. El Oussini H; Bayer H; Scekic-Zahirovic J; Vercruysse P; Sinniger J; Dirrig-Grosch S; Dieterlé S; Echaniz-Laguna A; Larmet Y; Müller K; Weishaupt JH; Thal DR; van Rheenen W; van Eijk K; Lawson R; Monassier L; Maroteaux L; Roumier A; Wong PC; van den Berg LH; Ludolph AC; Veldink JH; Witting A; Dupuis L Acta Neuropathol; 2016 Mar; 131(3):465-80. PubMed ID: 26744351 [TBL] [Abstract][Full Text] [Related]
40. Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). Niebrój-Dobosz I; Dziewulska D; Kwieciński H Folia Neuropathol; 2004; 42(3):151-6. PubMed ID: 15535033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]